GENET archive


7-Business: EU Commissioner for Enterprise and Industry calls for science-based debate on biotechnology

------------------------------- GENET-news -------------------------------

TITLE:  Biotechnology debate must remain science-based, says Verheugen
SOURCE: Cordis News, Luxembourg
DATE:   28 Sep 2005

------------------ archive: ------------------

Biotechnology debate must remain science-based, says Verheugen

The EU Commissioner for Enterprise and Industry, Günter Verheugen, has
reiterated the need for an open debate on the benefits of biotechnology
and the ethical questions surrounding it, but insisted that such a
dialogue must remain science-based.

Mr Verheugen was outlining the Commission's biotech policy at a high
level roundtable organised by the European association for bioindustries,
EuropaBio. He said that if Europe is to compete with the US and other
emerging challengers, then knowledge-based sectors, including
biotechnology, would have to be at the forefront of the Commission's policies.

'It is my objective to ensure that we create the conditions so that
Europe becomes the natural home for biotechnological innovation,' said Mr
Verheugen. He went on to outline the areas where the Commission would
concentrate its efforts in order to achieve this goal.

Support for innovation and the general science base are 'critical issues'
for the Commission, but equally important is making sure that innovations
result in applications that generate revenues. The new Competitiveness
and Innovation Programme (CIP) is designed to do precisely that, said Mr
Verheugen, by developing the innovative capacity of enterprise and industry.

The worrying trend of pharmaceuticals actors relocating their research
and development (R&D) activities outside Europe was also highlighted by
Mr Verheugen as an area for action. 'We must not underestimate this
widening gap. Losing R&D in life sciences is going to have major social
and economic consequences for Europe,' he said.

What is needed is an overall strategy for biotechnology, said the
Commissioner, and fortunately for the EU it already exists. The
Commission's Biotechnology Strategy, published in 2002, lays the
groundwork for Europe's catch-up efforts and covers all fields of biotech
- green, white and red. Mr Verheugen acknowledged the need to address
societal concerns concerning biotechnology, however, and said that the
Commission would launch a debate as part of the mid-term review of the
strategy in 2006.

'The debate must, however, remain science based, and we must take a
balanced view on matters of concern, such as GMOs, and avoid taking
extreme positions. Clarity and knowledge will help to lower emotional
prejudices,' he said, before highlighting the potential of genetically
modified organisms to provide better crop yields, increased
sustainability and better food and feed quality.

'However, we all know that public attitudes as well as Member States'
positions hamper the development in this area. [...] Europe has to make
its mind up whether it wants to use the full potential of green biotech
to become competitive vis-à-vis countries like the USA, Canada,
Australia, China and India,' the Commissioner argued.

'By keeping Europe at the cutting edge of biotechnology research, we will
[...] contribute to the more general goals of creating more highly-
qualified and well-paid jobs, boost economic growth and improve our terms
of trade. Let's be clear: it will not be an easy task to achieve this
[but] I am convinced we are able to face the challenge and come out
successful,' Mr Verheugen concluded.

To download the full text of Mr Verheugen's speech (in PDF format),
please click here:


European NGO Network on Genetic Engineering

Hartmut MEYER (Mr)
In den Steinäckern 13
D - 38116 Braunschweig

P: +49-531-5168746
F: +49-531-5168747
M: +49-162-1054755
E: coordination(*)
W: <>

   GENET-news mailing list